Advanced searches left 3/3

Multiple Myeloma - Springer Nature

Summarized by Plex Scholar
Last Updated: 13 May 2022

* If you want to update the article please login/register

A cross-sectional observational study of health-related quality of life in adults with multiple myeloma

Background This paper is intended to outline health-related quality of life in a United States based sample of multiple myeloma patients and determine risk factors for poor HRQoL. Patients and methods MM patients gathered through a Southeastern U. S. medical center's Tumor Registry were sent surveys assessing patient characteristics and HRQoL results. HRQoL domain scores were summarized, and the best subset linear regression method was used to predict predictors of HRQoL. Respondents reported global physical fitness, global mental stability, and physical fitness as significantly poor as the general population mean of 50. HRQoL findings were not related to treatment status and time since diagnosis. Patients with MM have significantly lower HRQoL than the general population. More research is needed to better understand the association between treatment regimens and HRQoL in patients with MM, as well as identify successful interventions.

Source link: https://doi.org/10.1007/s00520-022-06943-5


Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections

Introduction By guidelines for patients with IgG level 4 g/l and more than 3 infections or a severe infection, guidelines for patients with secondary immunodeficiency, immunoglobulin replacement therapy is recommended. If IgG level 4 g/l and/or 1–3 less prevalent infections have been identified, IgRT may be beneficial, although IgG level 4 g/l and/or 1–3 less common infections have been reported. Multiple myeloma and chronic lymphocytic leukemia patients were among the patients with chronic lymphocytic leukemia and multiple myeloma patients with chronic lymphocytic leukemia. The medications and infection data were obtained from patients with chronic lymphocytic leukemia and multiple myeloma patients. During therapy, 34. 8% of all patients had IgG deficiency and 34. 8% of all patients had IgG deficiency during therapy. In 23. 5% of CLL and 14. 4% of MM patients, IgRT was administered in 23. 5% of CLL and 14. 4%. GLAD in hypogammaglobulinemia and a hint of IgRT was 23. 3% of 86 CLL and 22. 1 percent of 77 MM patients, with 23. 3% in hypogaglobulinemia and 22. 2 percent of 77 MM patients. Without GLAD, the hazard ratio for any disease was 4. 49 and for severe infections 10. 64. Conclusions - Guideline adherence correlated with fewer and less common infections, but not so well in patients with a risk of IgRT. Patients with IgRT were markedly lower risk of severe infections.

Source link: https://doi.org/10.1007/s00520-022-06920-y


Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma

Abstract Plasmacytoma has been shown to have a poor prognosis in patients with multiple myeloma. Patients with initial plasmacytoma were more likely to experience plasmacytoma at MM relapse than those without initial plasmacytoma. Patients with plasmacytoma at relapse were much shorter overall survival than those without plasmacytoma, according to a median follow-up of 66. 0 months, but patients with EMD and PMD did not significantly differ between patients with EMD and those with PMD. Following MM relapse, all patients received return therapy, and progression-free survival was much shorter in patients with plasmacytoma than in those without. Plasmacytoma was often diagnosed at MM relapse after upfront ASCT in patients with plasmacytoma at the time of diagnosis, according to this report.

Source link: https://doi.org/10.1007/s00277-022-04776-0


Symptom clusters and quality of life in ambulatory patients with multiple myeloma

Purpose The aim of this research was to investigate symptom clusters and related clinical conditions in ambulatory multiple myeloma patients undergoing medication therapy. We also sought to determine the correlations between symptom clusters and patient quality of life. Methods included in this report were a total of 174 multiple myeloma patients hospitalized in the haematology day unit. The Chinese version of the Condensed Memorial Symptom Assessment Scale assessed symptoms. In multiple myeloma patients, we found three symptom clusters: psychological; exhaustion, dry mouth, and insomnia; and a fatigue symptom cluster. Patients can be divided into a severe-symptom group or a mild-symptom group based on the severity of symptoms. Patients' quality of life were adversely correlated with symptom cluster distress. Multiple signs are present in multiple symptom clusters in patients undergoing anticancer medication therapy, including multiple myeloma patients.

Source link: https://doi.org/10.1007/s00520-022-06896-9


Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma

Ribonucleotide reductase is the rate-limiting enzyme for the deoxyribonucleotide deoxyribonucleotides biosynthesis, which are critical for DNA replication and DNA damage repair. In addition, we investigated the clinical relevance and safety of HDS in patients with MM. Methods We used bioinformatic, genetic, and pharmacological methods to show that HDS was a RNR inhibitor that directly linked to RNR subunit M2 of RNR subunit M2. To determine safety and effectiveness, we also initiated a phase I clinical trial of single-agent HDS in MM patients to determine safety and effectiveness. Consequently, RNR-mediated dNTP synthesis and concomitantly inhibited DNA damage repair, resulting in endogenous unrepaired DNA double-strand breaks and inducing apoptosis, resulting in endogenous DNA double-strand breaks, preventing MM cell proliferation and inducing apoptosis. Conclusions Our report provides a rationale for the clinical testing of HDS as an anti-myeloma drug, either alone or in combination with standard MM therapy.

Source link: https://doi.org/10.1186/s12929-022-00813-2


Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805)

We used real-world reports from the Korean Myeloma Registry to analyze the characteristics and clinical outcomes of newly diagnosed MM patients with a t/del or t/del anomaly; Group 1: t or t; Group 2: del; Group 3: t/del; Group 1: t/del; Group 3: t or t; Group 1: del; Group 2: t or t; Group 1: t/del PFS and OS were significantly poorer in Group 3 among transplant-eligible patients, and even worse in those with gain after stratification by transplantation. Patients stratified by cytogenetic abnormality and the new International Staging System had radically different PFS and OS, with the worst survival in R-ISS III/Group 3 being the lowest survivors.

Source link: https://doi.org/10.1007/s12185-022-03332-w


Presence of bone marrow fibrosis in multiple myeloma may predict extramedullary disease

We reviewed the prevalence of bone marrow fibrosis in 91 newly diagnosed Japanese multiple myeloma patients and explored the effects of fibrosis on clinical characteristics and therapeutic outcomes. The presence of bone marrow fibrosis in laboratory results, the percentage of plasma cells in bone marrow or cytogenetic studies did not influence laboratory results, or cytogenetic results. In MM cells derived from bone marrow fibrosis patients, the expression of CD49e, an alpha5/beta1 integrin, was downregulated, according to an analysis of biological characteristics of MM cells. Five of the original 34 patients were re-evaluated for fibrosis grading after therapy, and five of them showed a decrease in fibrosis.

Source link: https://doi.org/10.1007/s12185-022-03373-1


Progress of modern imaging modalities in multiple myeloma

Multiple myeloma is an incurable hematological disease, but treatments have markedly improved the patient's prognosis in the last two decades. Whole-body low-dose computed tomography is replacing conventional skeletal survey by whole-body X-rays. Magnetic resonance imaging and positron-emission tomography have also become popular imaging techniques for MM diagnosis, extravascular disease, treatment success, and prognosis.

Source link: https://doi.org/10.1007/s12185-022-03360-6


Multiple myeloma with high-risk cytogenetics and its treatment approach

According to newer clinical trials, extended therapy may help patients with HRCAs develop MRD-negativity, resulting in improved outcomes. Tumor characteristics are determined by genetic variants and drug sensitivity of the disease, which are essential in determining tumor characteristics. This paper discusses the clinicopathologic features of genetic abnormalities related to adverse prognosis, focusing on HRCAs that are the most relevant in clinical research, as well as current optimal therapeutic strategies for newly diagnosed MM with HRCAs.

Source link: https://doi.org/10.1007/s12185-022-03353-5


KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma

In newly diagnosed, high-risk multiple myeloma, Bortezomib, lenalidomide, and dexamethasone induction is recommended long before autologous hematopoietic cell transplantation in newly diagnosed, high-risk multiple myeloma. Carfilzomib is another proteasome inhibitor that has been approved for MM. We compared results in ND-HRMM with pre-transplant KRD or VRD induction in this single-center, retrospective review. These were 38. 1%/42. 9%/100% with KRD at day 100 post-auto-HCT, versus 35. 1%/49. 8%/12. 8% with VRD. Patients with minimal residual disease (negative CR), 11 KRD, and 7 VRD patients had minimal residual disease – no CR – with minimal residual disease. Respective 3-year PFS and OS were 52% and 92% for KRD, 64% and 82% for VRD. Overall, the KRD induction pre-auto-HCT does not have a positive effect on outcomes, although it does not improve outcomes.

Source link: https://doi.org/10.1038/s41409-022-01697-4

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions